Easing Access to Bariatric Surgery Over Weight Loss Drugs by Some Insurers
Amid growing concerns regarding the expense associated with using glucagon-like peptide 1 agonists for obesity treatment, certain insurers are imposing additional restrictions or discontinuing coverage for these drugs altogether. Concurrently, there is a trend among healthcare plans to either maintain a certain level of accessibility to bariatric surgery or streamline the process for patients to […]
Easing Access to Bariatric Surgery Over Weight Loss Drugs by Some Insurers Read More »